Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review-Reference-Cited by-同舟云学术

Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review

Published:2017-09-19 Issue:12 Volume:27 Page:1329-1340
ISSN:1354-3776
Container-title:Expert Opinion on Therapeutic Patents
language:en
Short-container-title:Expert Opinion on Therapeutic Patents

Author:

Penning Trevor M.¹

Affiliation:

1. Center of Excellence in Environmental Toxicology & Department of Systems Pharmacology & Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

Funder

National Institutes of Health

Publisher

Informa UK Limited

Subject

Drug Discovery,Pharmacology,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/13543776.2017.1379503

Reference74 articles.

1. Aldo-Keto Reductases and Bioactivation/Detoxication

2. Human aldo–keto reductases: Function, gene regulation, and single nucleotide polymorphisms

3. Overexpression of aldo-keto reductase 1C3 (AKR1C3) in LNCaP cells diverts androgen metabolism towards testosterone resulting in resistance to the 5α-reductase inhibitor finasteride

Cited by 72 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ferroptosis in thyroid cancer: Potential mechanisms, effective therapeutic targets and predictive biomarker;Biomedicine & Pharmacotherapy;2024-08

2. Polymorphisms in drug-metabolizing genes and urinary bladder cancer susceptibility and prognosis: Possible impacts and future management;Gene;2024-05

3. Design and Evaluation of NSAID Derivatives as AKR1C3 Inhibitors for Breast Cancer Treatment through Computer-Aided Drug Design and In Vitro Analysis;Molecules;2024-04-16

4. Real-World Evidence of Triplet Therapy in Metastatic Hormone-Sensitive Prostate Cancer: An Austrian Multicenter Study;Clinical Genitourinary Cancer;2024-04

5. AKR1C3 in carcinomas: from multifaceted roles to therapeutic strategies;Frontiers in Pharmacology;2024-03-08